Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN-102)

The purpose of this study is to: • Observe how LEN moves throughout the body in US cisgender women • Evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women • valuate the acceptability of LEN injections and oral F/TDF in US cisgender women Cisgender means whatever gender you are now is the same as the sex that you were assigned at birth.